FATE — FATE THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1434316 ·
Last close
$1.02
Market Cap
$124.00M
52W High
$3.23
52W Low
$0.95
ADV30
1,516,698
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -32,247,000 | -30,687,000 | 238,275,000 | 43,942,000 | 105,243,000 |
| Jun 2026 | 2,082,000 | — | -31,134,000 | -30,159,000 | 260,103,000 | 32,429,000 | 106,665,000 |
| Mar 2026 | 1,299,000 | — | -33,000,000 | -31,213,000 | 284,916,000 | 39,570,000 | 105,209,000 |
| Dec 2025 | 1,369,000 | — | -34,721,000 | -32,374,000 | 318,937,000 | 46,628,000 | 111,753,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-101,944,000
Investing CF
$87,046,000
Financing CF
$5,490,000
CapEx
$-3,714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.05
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,595,681,000
Inventory
—
Receivables
$703,000
ST Investments
$121,341,000
EBIT TTM
$-133,590,000
Pretax Income TTM
$-125,996,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,491,000
EBITDA
$-120,502,000
Free Cash Flow
$-48,659,248
Enterprise Value
$143,575,952
Total Cash
$153,770,000
Total Debt
$75,675,000
Shares Out
121,568,755
Trailing EPS
$-1.03
Book Value
$1.80
ROE
-60.8%
ROA
-26.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,646,000 | -147,704,000 | -136,315,000 | 318,937,000 | 111,753,000 | 207,184,000 | -106,084,000 |
| Dec 2024 | 13,631,000 | -195,539,000 | -186,262,000 | 440,694,000 | 121,968,000 | 318,726,000 | -122,874,000 |
| Dec 2023 | 63,533,000 | -190,511,000 | -160,928,000 | 506,217,000 | 137,800,000 | 368,417,000 | -132,263,000 |
| Dec 2022 | 96,300,000 | -308,386,000 | -281,721,000 | 705,561,000 | 221,622,000 | 483,939,000 | -248,208,000 |
TTM Snapshot
Revenues TTM
$6,491,000
NetIncome TTM
$-125,996,000
OpCashFlow TTM
—
Assets (Latest)
$260,103,000
Forward EPS
$-0.97
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.05 · call volume: 1 · put volume: 600Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | $115.27M | $1.72 | — |
| CRDL | Cardiol Therapeutics Inc. | $113.53M | $0.97 | — |
| TARA | Protara Therapeutics, Inc. | $137.10M | $2.32 | — |
| HUMA | Humacyte, Inc. | $139.18M | $0.50 | — |
| LENZ | LENZ Therapeutics, Inc. | $109.97M | $3.50 | — |
News headlines (Yahoo Finance, 1h cache)
Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
2026-11-10 12:00 · Yahoo
Fate Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:16 · Yahoo
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-05 12:00 · Yahoo
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 21:05 · Yahoo
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
2026-10-26 11:00 · Yahoo
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
2026-10-12 11:00 · Yahoo
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
2026-10-01 11:00 · Yahoo
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
2026-09-25 11:00 · Yahoo
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
2026-09-03 11:00 · Yahoo
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.